China Net Interest Income from 2010 to 2026
| CPHI Stock | USD 0.65 0.02 3.17% |
Net Interest Income | First Reported 2019-03-31 | Previous Quarter -26.9 K | Current Value -23.8 K | Quarterly Volatility 59 K |
Check China Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among China Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.2 M, Interest Expense of 168.4 K or Selling General Administrative of 1.5 M, as well as many indicators such as Price To Sales Ratio of 9.82, Dividend Yield of 0.0 or PTB Ratio of 4.96. China financial statements analysis is a perfect complement when working with China Pharma Valuation or Volatility modules.
China | Net Interest Income | Build AI portfolio with China Stock |
The Net Interest Income trend for China Pharma Holdings offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether China Pharma is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest China Pharma's Net Interest Income Growth Pattern
Below is the plot of the Net Interest Income of China Pharma Holdings over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. China Pharma's Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in China Pharma's overall financial position and show how it may be relating to other accounts over time.
| Net Interest Income | 10 Years Trend |
|
Net Interest Income |
| Timeline |
China Net Interest Income Regression Statistics
| Arithmetic Mean | (490,336) | |
| Coefficient Of Variation | (45.30) | |
| Mean Deviation | 194,018 | |
| Median | (474,920) | |
| Standard Deviation | 222,138 | |
| Sample Variance | 49.3B | |
| Range | 571.5K | |
| R-Value | 0.90 | |
| Mean Square Error | 10.4B | |
| R-Squared | 0.80 | |
| Slope | 39,427 | |
| Total Sum of Squares | 789.5B |
China Net Interest Income History
About China Pharma Financial Statements
Investors use fundamental indicators, such as China Pharma's Net Interest Income, to determine how well the company is positioned to perform in the future. Although China Pharma's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | -169.6 K | -178.1 K |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of China Pharma Correlation against competitors. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is there potential for Pharmaceuticals market expansion? Will China introduce new products? Factors like these will boost the valuation of China Pharma. Projected growth potential of China fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.47) | Revenue Per Share | Quarterly Revenue Growth 0.109 | Return On Assets | Return On Equity |
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between China Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding China Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, China Pharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.